NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late
clinical-stage nanomedicine company pioneering novel approaches for
the local treatment of cancer, announced today that Bpifrance has
awarded the Company an interest-free loan of €2M for Innovation
(prêt à taux zéro pour l'Innovation - PTZI).
The interest-free loan, repayable from September
2019, aims to support the development of Nanobiotix's lead product,
NBTXR3, which is currently under registration trial (Phase II/III)
with Soft Tissue Sarcoma. Nanobiotix has recently filed for a CE
Mark for the product.
A nanomedicine product in registration
phase
NBTXR3 is a first-in-class radio-enhancer based
on the NanoXray technology, designed for direct injection into
cancerous tumors. The product is engineered to increase the dose
and efficacy of radiotherapy without increasing toxicity or causing
damage to surrounding healthy tissues.
NBTXR3 is currently in clinical development in
six indications: Soft Tissue Sarcoma, Head and Neck cancers,
Prostate, Liver cancers (primary and metastases) and rectal (via
PharmaEngine, partner for the Asia Pacific area).
Philippe Mauberna, CFO of Nanobiotix, commented:
"Bpifrance has shown Nanobiotix a continual high level of support
since our inception for which we are very pleased. This
interest-free loan will contribute to financing the last steps of
the NBTXR3 registration study in Soft Tissue Sarcoma. This is an
exciting period for the Company."
Bpifrance, a historic partner of the
Company
Bpifrance (ex OSEO), has supported Nanobiotix's
dynamic development for over 12 years. This support has taken a
number of forms such as repayable grants or inclusion in Strategic
Industrial Innovation (ISI) programs, such as the "NICE project", a
collaborative project dedicated to liver cancers and managed by
Bpifrance.
Eric Tossah, Bpifrance, commented: « The Bpifrance team is
delighted to put this new loan together for Nanobiotix which
demonstrates our deep support and confidence in this innovative
French technology. Nanobiotix is rapidly growing with an
international and renowned management team. They launched an
affiliate in the Boston area two years ago, and have welcomed a
number of North American life sciences specialist
investors. »
About NANOBIOTIX:
www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205)
is a late clinical-stage nanomedicine company pioneering novel
approaches for the local treatment of cancer. The Company's
first-in-class, proprietary technology, NanoXray, enhances
radiotherapy energy with a view to provide a new, more efficient
treatment for cancer patients.
NanoXray products are compatible with current
radiotherapy treatments and are meant to treat potentially a wide
variety of solid tumors including soft tissue sarcoma, head and
neck cancers, liver cancers, prostate cancer, breast cancer,
glioblastoma, etc., via multiple routes of administration.
Nanobiotix's lead product NBTXR3, based on
NanoXray, is currently under clinical development for soft tissue
sarcoma, head and neck cancer, prostate cancer, rectal cancer
(PharmaEngine) and liver cancers (HCC and liver metastases). The
Company has partnered with PharmaEngine for clinical development
and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of
Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO,
Bloomberg: NANO: FP). The Company Headquarter is based in Paris,
France. Affiliate in Cambridge, United States.
For more information, please visit
www.nanobiotix.com
About Bpifrance: www.bpifrance.fr
Bpifrance, a subsidiary of the
French state and the "Caisse des Dépôts" and the entrepreneurs'
trusted partner, finances businesses from the seed phase to
IPO, through loans, guarantees and equity investments.
Bpifrance also provides operational
services and strong support for innovation, export, and external
growth in partnership with Business France and Coface. Bpifrance
offers to businesses a large range of financing opportunities at
each key step of their development, including offers adapted to
regional specificities. With its 45 regional offices (90% of
decisions are made locally) Bpifrance represents a strategic tool
for economic competitiveness dedicated to entrepreneurs.
Bpifrance acts as a back-up for
initiatives driven by the French State and the Regions to tackle 3
goals:
- Contributing to SME's growth
- Preparing tomorrow's competitiveness
- Contributing to the development of a positive entrepreneur
ecosystem.
With Bpifrance, businesses benefit from a
powerful, efficient and close representative, to answer all their
needs in terms of financing, innovation and investment.
More info: www.bpifrance.fr - Follow us:
@bpifrance
Contact
Nanobiotix |
|
|
Sarah Gaubert Head of Communication and Public Affairs +33
(0)1 40 26 07 55 contact@nanobiotix.com |
|
|
Media relations |
France - NewCap
Annie-Florence Loyer +33 (0)6 88 20 35 59
afloyer@newcap.fr |
|
EU
Outside France - Instinctif Partners Melanie Toyne
Sewell +44 (0) 207 457 2020 nanobiotix@instinctif.com |
United States -
The Ruth Group Kirsten Thomas / Chris Hippolyte +1
508-280-6592 / +1 646-536-7023 Nanobiotix@theruthgroup.com |
Disclaimer
This press release contains certain
forward-looking statements concerning Nanobiotix and its business.
Such forward-looking statements are based on assumptions that
Nanobiotix considers to be reasonable. However, there can be no
assurance that the estimates contained in such forward-looking
statements will be verified, which estimates are subject to
numerous risks including the risks set forth in the reference
document of Nanobiotix filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) under number D.16-0732
on July 22, 2016 (a copy of which is available on
www.nanobiotix.com) and to the development of economic conditions,
financial markets and the markets in which Nanobiotix operates. The
forward-looking statements contained in this press release are also
subject to risks not yet known to Nanobiotix or not currently
considered material by Nanobiotix. The occurrence of all or part of
such risks could cause actual results, financial conditions,
performance or achievements of Nanobiotix to be materially
different from such forward-looking statements.
This press release and the information that it
contains do not constitute an offer to sell or subscribe for, or a
solicitation of an offer to purchase or subscribe for, Nanobiotix
shares in any country.
Nanobiotix (EU:NANO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Sep 2023 to Sep 2024